Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Alfuzosin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D known ✓ | P25100 | 3/20 | 0.54 |
| ▸ | ADRA1A known ✓ | P35348 | 3/20 | 0.54 |
| ▸ | ADRA1B known ✓ | P35368 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.54 |
| ▸ | HPGD | P15428 | 8/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.54 |
| ▸ | GLA | P06280 | 5/20 | 0.54 |
| ▸ | GAA | P10253 | 4/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.54 |
| ▸ | SLC22A1 | O15245 | 2/20 | 0.54 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.54 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.54 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.54 |
| ▸ | ACHE | P22303 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.54 |
| ▸ | DRD3 | P35462 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alfuzosin SCHEMBL8094025 | 0.97 | ALDH1A1 (0.58) | ALDH1A1HPGDHSD17B10KDM4EGLA | |
| Alfuzosin SCHEMBL8108092 | 0.92 | ALDH1A1 (0.61) | ALDH1A1HPGDHSD17B10KDM4EGLA | |
| Alfuzosin SCHEMBL8109775 | 0.92 | ADRA1D (0.46) | ALDH1A1HPGDHSD17B10KDM4EGLA | |
| Alfuzosin SCHEMBL8103953 | 0.91 | KDM4E (0.66) | ALDH1A1HPGDHSD17B10KDM4EGLA | |
| Alfuzosin SCHEMBL8094004 | 0.89 | KDM4E (0.68) | ALDH1A1HPGDHSD17B10KDM4EGLA | |
| Alfuzosin SCHEMBL8094247 | 0.89 | ADRA1D (0.49) | ALDH1A1HPGDHSD17B10KDM4EGLA | |
| Alfuzosin SCHEMBL8097824 | 0.88 | KDM4E (0.70) | ALDH1A1HPGDHSD17B10KDM4EGLA | |
| Alfuzosin SCHEMBL8107125 | 0.88 | KDM4E (0.70) | ALDH1A1HPGDHSD17B10KDM4EGLA | |
| Alfuzosin SCHEMBL8104069 | 0.87 | ALDH1A1 (0.46) | ALDH1A1HPGDHSD17B10KDM4EGLA | |
| Alfuzosin SCHEMBL8103934 | 0.85 | HPGD (0.74) | ALDH1A1HPGDHSD17B10KDM4EGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080039473-A1 | PREPARATION AND UTILITY OF SUBSTITUTED QUINAZOLINE COMPOUNDS WITH ALPHA-ADRENERGIC BLOCKING EFFECTS | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039473-A1 | PREPARATION AND UTILITY OF SUBSTITUTED QUINAZOLINE COMPOUNDS WITH ALPHA-ADRENERGIC BLOCKING EFFECTS | ADRB1, ADRB2, ADRB3 | ADRA1D 9/4885ADRA1A 8/4885ADRA1B 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.